Marinomed Biotech AG confirmed its financial outlook for the fiscal year 2022. The company expects continued growth of Carragelose revenues and a slight increase in R&D expenses, and consequently an operating loss for 2022. Marinomed plans to reach operating profitability in the medium term.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14 EUR | -0.71% | -4.44% | -52.05% |
May. 22 | Transcript : Marinomed Biotech AG, Q1 2024 Earnings Call, May 22, 2024 | |
Apr. 16 | Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-52.05% | 23.39M | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- MARI Stock
- News Marinomed Biotech AG
- Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022